Nordicus Partners Corporation announced it entered into a paying Consultancy Agreement with Orocidin A/S in Denmark. Orocidin A/S ("Orocidin") is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the preferred treatment against aggressive periodontitis. Orodicin chose Nordicus as their exclusive consulting partners to assist with getting established on the U.S. marketplace and becoming Nordicus?

first revenue generating customer. As Orocidin advances in its development of drugs against periodontitis, Nordicus might further consider taking a significant equity stake in Orodicin.